In December 2019, a novel pneumonia caused by a previously unknown pathogen emerged
in Wuhan, a city of 11 million people in central China. The initial cases were linked to …

A new coronavirus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
is the aetiological agent responsible for the 2019–2020 viral pneumonia outbreak of …

The antineoplastic drug carmofur is shown to inhibit the SARS-CoV-2 main protease (M pro ).
Here, the X-ray crystal structure of M pro in complex with carmofur reveals that the carbonyl …

The SARS-CoV-2 pandemic has triggered global efforts to develop therapeutics. The main
protease of SARS-CoV-2 (M pro ), critical for viral replication, is a key target for therapeutic …

Since December 2019, the pandemic of coronavirus disease 2019 (COVID-19) has taken a
heavy toll on global health, creating an urgent need to develop effective strategies for …

The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) urgently needs an effective cure. 3CL …

Background Simnotrelvir is an oral 3-chymotrypsin–like protease inhibitor that has been
found to have in vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-…

The COVID-19 pandemic caused by nonstop infections of SARS-CoV-2 has continued to
ravage many countries worldwide. Here we report that suramin, a 100-year-old drug, is a …

A new coronavirus (SARS-CoV-2) has been identified as the etiologic agent for the COVID-19
outbreak. Currently, effective treatment options remain very limited for this disease; …

Human infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cause
coronavirus disease 19 (COVID-19) and there is currently no cure. The 3C-like protease (…